Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$61.8MCash on Hand
25.6mo Cash Runway
Follow MSLE by emailGet an email when MSLE reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about MSLE, unsubscribe in one click. Privacy
📣 What MSLE Says Is Next
fourth quarter of 2026 · Forazapadin: “Following FDA clearance of an Investigational New Drug (IND) application, a Phase 2 clinical trial of forazapadin in adults with facioscapulohumeral muscular dystrophy (FSHD) is expected to begin in the fourth quarter of 2026.”
Company press release, Oct 21, 2026 · SEC filing
fourth quarter of 2026 · “A Phase 2 clinical study to evaluate the safety, efficacy and tolerability of forazapadin in adults with FSHD is expected to begin in the fourth quarter of 2026.”
Company press release, Oct 5, 2026 · SEC filing
first quarter of 2027 · “Accordingly, we are adjusting our previous plan for releasing data and now intend to share topline clinical data in the first quarter of 2027.” “The enthusiasm and commitment of the Duchenne community have enabled us to exceed our enrollment target and build a robust global study,” said Wildon Farwell, M.D., chief medical officer of Satellos.”
Company press release, Sep 30, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 6, 2026 ·
Clinical trial Satellos changed the primary efficacy endpoint of its BASECAMP Phase 2 pediatric DMD trial from dynamometry to change in MRI-measured vastus lateralis fat fraction after FDA feedback. Topline 12-week placebo-controlled data are expected in Q1 2027. Form 6-K · SEC filing · Press release
Nov 5, 2026 ·
Satellos will host an investor conference call and audio webcast on Friday, Nov. 6, 2026, at 8:00 a.m. ET to update on the clinical and regulatory strategy for its BASECAMP Phase 2 pediatric study of forazapadin in Duchenne muscular dystrophy. CEO Frank Gleeson and CMO Wildon Farwell will speak. Form 6-K · SEC filing · Press release
Oct 27, 2026 ·
Leadership Satellos formed a Scientific Advisory Board of six researchers in stem cell biology, regenerative medicine, neuroscience and chemistry to advise on regeneration, aging and neurodegeneration research. Janet Rossant will chair the board. Form 6-K · SEC filing · Press release
Oct 21, 2026 ·
Satellos will present at the Guggenheim Healthcare Innovation Conference on Nov. 9, 2026 (fireside chat at 9:30 a.m. ET in Boston) and the Jefferies Global Healthcare Conference on Nov. 18-19, 2026 in London. Leadership will also hold one-on-one investor meetings. Form 6-K · SEC filing · Press release
Oct 5, 2026 ·
Satellos announced U.S. Patent No. 12,747,245 covering composition of matter claims for lead candidate forazapadin, providing protection through Sept. 6, 2044, with possible Patent Term Extension after U.S. approval. Form 6-K · SEC filing · Press release
Sep 30, 2026 ·
Clinical trial Completed enrollment in the Phase 2 BASECAMP trial of forazapadin in ambulatory boys 7 to 10 with Duchenne muscular dystrophy, exceeding its enrollment target within nine months. Topline data now expected in Q1 2027, later than previously planned. Form 6-K · SEC filing · Press release
Sep 24, 2026 ·
Regulatory FDA cleared the IND application for forazapadin in facioscapulohumeral muscular dystrophy (FSHD), with a Phase 2 study expected to begin in Q4 2026. The FSHD Canada Foundation agreed to provide up to US$5 million in milestone payments over five quarters in exchange for a capped revenue-sharing interest. Form 6-K · SEC filing · Press release
Sep 15, 2026 ·
Satellos will present four poster presentations at the 31st Annual Congress of the World Muscle Society in Hiroshima, Japan, from Sept. 29 to Oct. 3, 2026, including Phase 2 data posters on forazapadin (SAT-3247) in Duchenne muscular dystrophy. No new topline results are disclosed in the release. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Mar 2027 · Phase 2 · Active Trial · Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients Registry primary completion date, not a results date
Sep 2027 · Phase 2 · Enrolling · An Open-label Long-term Follow-up Study of SAT-3247 for Participants With Duchenne Muscular Dystrophy Including Those Who Participated in SAT-3247-CL-101 Registry primary completion date, not a results date
Dec 2028 · Phase 2 · Upcoming Trial · A Study of SAT-3247 to Evaluate the Safety, Tolerability, and Efficacy in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
MSLE holds $61.8M in cash and short-term investments and burns about $7.3M/quarter from operations,
an estimated runway of 25.6 months at that rate (BioRadar estimate, not company guidance).
Share count 15,458,903 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full MSLE picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MSLE and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.